Brian B Haab
Overview
Explore the profile of Brian B Haab including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
2512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Binkowski B, Klamer Z, Gao C, Staal B, Repesh A, Tran H, et al.
Sci Adv
. 2025 Mar;
11(10):eadt0029.
PMID: 40053601
Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays for early disease detection. We hypothesized that PDAC cell subpopulations could be identified by aberrant glycan signatures in...
2.
Longo J, DeCamp L, Oswald B, Teis R, Reyes-Oliveras A, Dahabieh M, et al.
bioRxiv
. 2024 Oct;
PMID: 39464161
Glucose is essential for T cell proliferation and function, yet its specific metabolic roles remain poorly defined. Here, we identify glycosphingolipid (GSL) biosynthesis as a key pathway fueled by glucose...
3.
Binkowski B, Klamer Z, Gao C, Staal B, Repesh A, Tran H, et al.
bioRxiv
. 2024 Sep;
PMID: 39229066
Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays suitable for early disease detection that would improve patient outcomes. The CA19-9 glycan is currently used as a...
4.
Lu X, McDowell C, Blaschke C, Liu L, Grimsley G, Wisniewski L, et al.
Anal Chem
. 2023 May;
95(19):7475-7486.
PMID: 37126482
Sialic acid isomers attached in either α2,3 or α2,6 linkage to glycan termini confer distinct chemical, biological, and pathological properties, but they cannot be distinguished by mass differences in traditional...
5.
Wisniewski L, Braak S, Klamer Z, Gao C, Shi C, Allen P, et al.
Front Oncol
. 2023 May;
13:1135405.
PMID: 37124496
Introduction: Outcomes following tumor resection vary dramatically among patients with pancreatic ductal adenocarcinoma (PDAC). A challenge in defining predictive biomarkers is to discern within the complex tumor tissue the specific...
6.
Wisniewski L, Braak S, Klamer Z, Gao C, Shi C, Allen P, et al.
bioRxiv
. 2023 Jan;
PMID: 36711795
Outcomes following tumor resection vary dramatically among patients with pancreatic cancer. A challenge in defining predictive biomarkers is to discern within the complex tumor tissue the specific subpopulations and relationships...
7.
Klamer Z, Harris C, Beirne J, Kelly J, Zhang J, Haab B
Glycobiology
. 2022 Mar;
32(8):679-690.
PMID: 35352123
Glycan arrays continue to be the primary resource for determining the glycan-binding specificity of proteins. The volume and diversity of glycan-array data are increasing, but no common method and resource...
8.
McDowell C, Klamer Z, Hall J, West C, Wisniewski L, Powers T, et al.
Mol Cell Proteomics
. 2021 Feb;
20:100012.
PMID: 33581409
The early detection of pancreatic ductal adenocarcinoma (PDAC) is a complex clinical obstacle yet is key to improving the overall likelihood of patient survival. Current and prospective carbohydrate biomarkers carbohydrate...
9.
Gao C, Wisniewski L, Liu Y, Staal B, Beddows I, Plenker D, et al.
Clin Cancer Res
. 2020 Oct;
27(1):226-236.
PMID: 33093149
Purpose: A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We hypothesized that a...
10.
Liu Y, Kaur S, Huang Y, Fahrmann J, Rinaudo J, Hanash S, et al.
Cancer Epidemiol Biomarkers Prev
. 2020 Jun;
29(12):2513-2523.
PMID: 32532830
Patients afflicted with pancreatic ductal adenocarcinoma (PDAC) face a dismal prognosis, but headway could be made if physicians could identify the disease earlier. A compelling strategy to broaden the use...